Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | BCDIN3D | Q7Z5W3 | 3/20 | 0.39 |
| ▸ | C1S | P09871 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | AGXT | P21549 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1766779 | 1.00 | GBA1 (0.47) | GBA1IDO1TDO2MAOASLC6A4 | |
| Hydrochloric Acid SCHEMBL17764491 | 0.98 | IDO1 (0.47) | GBA1IDO1TDO2MAOASLC6A4 | |
| SCHEMBL5712566 | 0.85 | SLC6A4 (0.48) | SLC6A4 | |
| SCHEMBL1419380 | 0.85 | GBA1 (0.45) | GBA1IDO1TDO2MAOASLC6A4 | |
| Hydrochloric Acid SCHEMBL16396955 | 0.83 | IDO1 (0.45) | GBA1IDO1TDO2MAOAALDH1A1 | |
| SCHEMBL1419673 | 0.82 | GBA1 (0.43) | GBA1IDO1TDO2MAOAALDH1A1 | |
| SCHEMBL1470710 | 0.82 | IDO1 (0.46) | GBA1IDO1TDO2MAOAALDH1A1 | |
| SCHEMBL4702287 | 0.82 | IDO1 (0.46) | GBA1IDO1TDO2MAOAALDH1A1 | |
| Hydrochloric Acid SCHEMBL17764375 | 0.80 | IDO1 (0.42) | GBA1IDO1TDO2MAOABCDIN3D | |
| SCHEMBL1419336 | 0.80 | SLC2A1 (0.45) | GBA1IDO1TDO2MAOABCDIN3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236055-B2 | Non-systemic TGR5 agonists | Venenum Biodesign, LLC (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200308122-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | Venenum Biodesign, LLC (US) | 2020-10-01 | — | — | US | disclosed |
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| EP-2297112-B1 | PYRAZOLE COMPOUNDS AS CCR1 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2013-04-03 | — | — | EP | disclosed |
| US-8338610-B2 | Pyridinyl compounds useful as intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-8293917-B2 | Pyrazole compounds as CCR1 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20110230521-A1 | Pyrazole Compounds As CCR1 Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| US-20110105798-A1 | SYNTHESIS OF CHIRAL AMINES | MERCK FROSST CANADA LTD. (CA) | 2011-05-05 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308122-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | GPR119, SSTR5, FFAR3 | GBA1 170/4885IDO1 2294/4885TDO2 2180/4885 |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | GBA1 2498/4885IDO1 166/4885TDO2 3131/4885 |
| US-11236055-B2 | Non-systemic TGR5 agonists | SSTR5, GPR119, FFAR3 | GBA1 191/4885IDO1 2023/4885TDO2 2016/4885 |
| US-20110230521-A1 | Pyrazole Compounds As CCR1 Antagonists | CCR1, CCR3, CCR4 | GBA1 2238/4885IDO1 187/4885TDO2 3352/4885 |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | CCR1, CCRL2, CCR4 | GBA1 892/4885IDO1 55/4885TDO2 1629/4885 |
| US-20110105798-A1 | SYNTHESIS OF CHIRAL AMINES | H1-5, HNMT, PNMT | GBA1 4252/4885IDO1 53/4885TDO2 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.